Descripción del proyecto
La próxima generación de investigación sobre organoides intestinales para la enfermedad inflamatoria intestinal
La enfermedad inflamatoria intestinal (EII) representa un espectro de trastornos intestinales que provocan la inflamación crónica del tracto digestivo. El desarrollo de nuevas plataformas de modelos de la enfermedad es fundamental para comprender los mecanismos fundamentales del trastorno. El proyecto SYNMAT FOR ORGANOIDS, financiado con fondos europeos, se ha propuesto desarrollar la próxima generación de organoides intestinales humanos usando la encapsulación de microfluidos en nichos sintéticos. Esta tecnología permitirá la fabricación en serie de organoides intestinales humanos para la modelización de enfermedades, el cribado de fármacos y aplicaciones de medicina regenerativa. El cocultivo de organoides intestinales humanos con células inmunitarias y microbiota recreará las condiciones naturales y proporcionará la próxima generación de organoides intestinales humanos, que sintetizará el complejo espectro de la EII y brindará nueva información sobre la etiología del trastorno.
Objetivo
Intestinal bowel disease (IBD) is a chronic immune-mediated disorder characterized by a complex spectrum of multifactorial disorders, which affects 2.5-4 million people in Europe with a total annual healthcare cost of €4.6-5.6 billion. The unknown aetiology of IBD, along with its heterogeneous and multifactorial nature, make essential the development of novel disease model platforms that enable the fundamental understanding of the disorder. My project aims to develop the next generation of human intestinal organoids (HIOs) in reproducible and high-throughput fashion by microfluidics encapsulation in synthetic niches. This scalable technology will provide a well-controlled mass production of HIOs for disease modelling, drug screening of novel therapeutic targets, and regenerative medicine applications, filling the translational gap with organoids research. I will co-culture HIOs with immune cells and microbiota to obtain native physiological similarities and to develop the next generation of HIOs, which can effectively recapitulate the complex multifactorial spectrum of IBD and allow the identification of new insights into the pathophysiology of the disorder. MSCA Fellowship will provide me with a unique opportunity to exploit my diverse skill set and take fully advantage of available facilities and partnerships of Prof. Andrés García and Prof. Abhay Pandit, who are uniquely positioned to maximize the output of this project and benefit my future career. I will be trained in both discipline-specific and complementary technical training and generic and complementary transferable skills training through an inter-sectoral secondment on a CÚRAM’s industrial partnership to translate this innovative therapeutic technology to the clinic. The disruptive technology developed through this proposal will represent a step change in our understanding of intestinal disorders and advanced therapies, entailing a great contribution to the European knowledge-based economy and society.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
H91 Galway
Irlanda